Rosemary F. Lawrence-Henderson
Pfizer (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Cancer Research and Treatments, Biosimilars and Bioanalytical Methods, Advanced Biosensing Techniques and Applications
Most-Cited Works
- → Pharmacokinetic, Biodistribution, and Biophysical Profiles of TNF Nanobodies Conjugated to Linear or Branched Poly(ethylene glycol)(2012)64 cited
- → A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers(2020)62 cited
- → One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics(2014)54 cited
- → An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts(2020)48 cited
- → Bioanalytical platform comparison using a generic human IgG PK assay format(2013)34 cited
- → Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model(2013)20 cited
- → A Multi-site In-depth Evaluation of the Quanterix Simoa from a User’s Perspective(2017)18 cited
- → Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors(2021)15 cited
- → A Competitive Ligand-Binding Assay to Detect Neutralizing Antibodies to a Bispecific Drug Using a Multiplex Meso Scale Discovery Platform(2021)3 cited
- → Figure S9 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers(2023)